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Abstract Atherogenic dyslipidemia comprises a triad
of increased blood concentrations of small, dense low-
density lipoprotein (LDL) particles, decreased high-density
lipoprotein (HDL) particles, and increased triglycerides.
A typical feature of obesity, the metabolic syndrome,
insulin resistance, and type 2 diabetes mellitus, atherogenic
dyslipidemia has emerged as an important risk factor for
myocardial infarction and cardiovascular disease. A number
of genes have now been linked to this pattern of lipoprotein
changes. Low-carbohydrate diets appear to have beneficial
lipoprotein effects in individuals with atherogenic dyslipi-
demia, compared to high-carbohydrate diets, whereas the
content of total fat or saturated fat in the diet appears to have
little effect. Achieving a better understanding of the genetic
and dietary influences underlying atherogenic dyslipidemia
may provide clues to improved interventions to reduce the
risk of cardiovascular disease in high-risk individuals.
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Definition of Atherogenic Dyslipidemia
Prospective epidemiologic studies have shown that blood
levels of low-density lipoprotein cholesterol (LDL-C) sig-
nificantly predict incident atherosclerotic cardiovascular
disease (CVD), and LDL-C-lowering therapy has been
repeatedly demonstrated in many populations to reduce
CVD risk. This has led to the formulation of risk prediction
algorithms for identification of high-risk individuals and
specific LDL-C goals to be achieved with lifestyle and
pharmacological interventions [1]. Many individuals with
normal LDL-C levels nevertheless develop CVD [2], par-
ticularly in older age groups.
There is considerable heterogeneity among low-density
lipoproteins (LDL), ranging from small, dense, lipid-
depleted particles to large, buoyant cholesterol-enriched
particles [3]. These particles have typically been grouped
into four categories ranging from LDL1 (largest) to LDL4
(smallest) and subdivided even further into as many as
eight subfractions. A number of studies have suggested that
small LDL particles carry disproportionate atherogenic risk
[4–7]. This suggests that treatment based on LDL-C levels
alone potentially provides a suboptimal treatment for a
significant proportion of at-risk individuals.
High-density lipoprotein cholesterol (HDL) also has a
strong epidemiological relationship with CVD, with
increased HDL-C levels protective against disease, and is
divided into two to three subfractions. As with LDL-C,
some studies suggest that specific HDL subfractions are
more predictive of CVD than HDL-C [8], whereas others
suggest no distinction [9–13].
Austin et al. first described a risk-conferring lipid/
lipoprotein profile, termed ‘‘atherogenic dyslipidemia’’ or
the ‘‘atherogenic lipoprotein phenotype,’’ that comprises a
higher proportion of small LDL particles, reduced HDL-C,
and increased triglycerides [14]. Atherogenic dyslipidemia
is characteristically seen in patients with obesity, the
metabolic syndrome, insulin resistance, and type 2 diabetes
mellitus [15, 16] and has emerged as an important marker
for the increased CVD risk observed in these populations.
Herein we review the present understanding of the
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contribution of atherogenic dyslipidemia to CVD, as well
as the genetic and dietary influences underlying atherogenic
dyslipidemia.
Small LDL Particles, Total LDL Particles, and CVD
Risk
Besides the traditional blood lipid measurements of
LDL-C, HDL-C, and triglycerides, there now exist a
number of alternative measures that assess lipoprotein
subfractions in some way. The best established is the
measurement of the blood concentration of apolipopro-
tein B (apoB). Each non-HDL particle—including LDL
particles, intermediate-density lipoprotein (IDL) particles,
very-low-density lipoprotein (VLDL) particles, chylomi-
crons, and their remnants—typically harbors one apoB
molecule. Thus, the apoB measure represents a count of
non-HDL particles circulating in the bloodstream. More
sophisticated techniques can quantify the numbers of
particle within each lipoprotein class, as well as within
subfractions of each lipoprotein class; in addition, peak
particle size within a class (e.g., LDL peak particle
diameter) can be calculated. These techniques include
analytical ultracentrifugation, gradient gel electrophore-
sis, nuclear magnetic resonance (NMR), and a relatively
new gas-phase differential electrophoretic macromolecu-
lar mobility-based method (termed as the ion mobility
method).
A number of studies have now used one of the lipo-
protein subfraction measurement techniques to assess
whether any of the subfractions have prognostic power for
CVD or intermediate endpoints for CVD such as coronary
calcium score or carotid intima-media thickness. Notably,
many of these studies find that the small LDL particle
concentration predicts cardiovascular endpoints compara-
bly to if not better than LDL-C [7, 17–21].
There is biological plausibility for a causal role of small
LDL particles in atherosclerotic disease, with evidence that
small, dense, lipid-poor LDL particles may be inherently
more atherogenic than large LDL particles [6]. They have
greater susceptibility to oxidation than larger particles and
thus may be more likely to instigate the inflammatory pro-
cesses in vascular endothelium that underlie atherosclerotic
disease. They bind more tightly to arterial proteoglycans and
may penetrate into the arterial wall more easily. Finally,
small LDL particles have relatively lower affinity for the
LDL receptor compared to mid-size particles, resulting in
decreased cellular uptake and increased time spent circu-
lating in the bloodstream, where the particles would have
prolonged influence on the atherosclerotic process.
However, each of the studies that have demonstrated
that small LDL particle concentrations are predictive of
cardiovascular endpoints also showed that the total LDL
particle number (LDL-P) is similarly predictive [7, 17–21].
This is because the small LDL particle number is highly
correlated with LDL-P. Intuitively, this can be explained
by the reasoning that among individuals with equal LDL-C
levels, the same of amount of cholesterol distributed among
a larger number of particles implies that the particles must
be of smaller size on average. It is possible, then, that all
LDL particles are similarly atherogenic and the association
of increased small LDL particle concentrations with dis-
ease is simply the result of the increased number of LDL
particles, rather than small LDL particles being uniquely
atherogenic. Epidemiological studies to date have not been
able to unequivocally distinguish between these two
possibilities.
Regardless of whether the small LDL particle number or
LDL-P is used, either offers prognostic information distinct
from the standard LDL-C measure obtained with a fasting
lipid profile. Reinforcing this point was the finding in the
Framingham Offspring Study that when participants were
divided into four groups—low LDL-C ? low LDL-P, low
LDL-C ? high LDL-P, high LDL-C ? low LDL-P, high
LDL-C ? high LDL-P—stratification by LDL-P markedly
discriminated by CVD event-free survival, whereas there
was no difference seen with stratification by LDL-C [22].
Given the data suggesting a particular role for small
LDL particles in CVD, and the epidemiological observa-
tion of the ‘‘atherogenic lipoprotein phenotype’’ of
increased small LDL particle numbers, decreased HDL-C,
and increased triglycerides, some lipoprotein assays have
defined cutoffs for LDL peak particle size, with high par-
ticle sizes designated as ‘‘pattern A’’ (normal; defined as
[25.5 nm when measured by gradient gel electrophoresis
[3]) and low particle sizes designated as ‘‘pattern B’’
(having an increased proportion of small LDL particles
and, thus, more likely to have atherogenic dyslipidemia;
defined as B25.5 nm when measured by gradient gel
electrophoresis) to aid clinicians in categorizing patients at
risk for CVD.
Principal Component Analysis of Lipoprotein
Subfractions
Although numerous studies have demonstrated that some
lipoprotein subfractions are predictive of CVD, none of
these studies systematically analyzed the interrelationships
among all of the various lipoprotein subfractions to deter-
mine whether there are distinct combinations of subfrac-
tions that independently confer cardiovascular risk. To
address this question, we have applied the technique of
principal component analysis to identify interrelated com-
binations of subfractions and determine their relationship
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with CVD in a large prospective cohort study, the Malmo¨
Diet and Cancer-Cardiovascular Cohort (MDC-CC) [23].
Principal component analysis is a statistical method that
analyzes the interrelationships between numerous variables
and yields a fewer number of components that explain most
of the correlation information of the original variables.
Each of the resulting components is an independent linear
combination of the original variables; furthermore, the
components are fully independent of one another, i.e., they
have zero correlation.
When we applied principal component analysis to
eleven lipoprotein subfractions measured by ion mobility
analysis of samples from more than 4,500 individuals in
MDC-CC, we identified three major independent compo-
nents, all of which were associated with incident CVD in
the cohort [23, 24]. Notably, one of the three components
represented a pattern of increased small and medium LDL
particle concentrations, decreased large HDL particle
concentrations, and increased triglycerides—corresponding
to atherogenic dyslipidemia. This component was much
more highly associated with incident CVD events (hazard
ratio of 1.22 per 1 standard deviation) than LDL-C (hazard
ratio of 1.10 per 1 standard deviation), indicating it to be a
superior predictor of disease [23]. The other two principal
components represented LDL-associated CVD risk (hazard
ratio of 1.10 per 1 standard deviation) and HDL-associated
CVD protection (hazard ratio of 0.81 per 1 standard devi-
ation). Thus, our analysis established that atherogenic
dyslipidemia is an epidemiologically distinct risk factor for
CVD than the traditional risk factors of LDL-C and HDL-C
and represents an independent mechanistic pathway con-
tributing to the pathogenesis of CVD. Accordingly, there is
a strong rationale to explore genetic and dietary modifiers
of this pathway in order to better craft targeted interven-
tions to reduce CVD risk.
Genetics and Atherogenic Dyslipidemia
Family-based segregation analyses suggest that the ath-
erogenic lipoprotein phenotype has a strong genetic basis
that likely reflects contributions from numerous genes
[14, 25, 26]. Candidate genes include those that influence
LDL peak particle size; family-based and twin studies
indicate a large heritable component of LDL size, ranging
from 40 to 60% of the trait. Genes with variants that have
been reported to be associated with LDL size include:
CETP, encoding cholesteryl ester transfer protein, which
exchanges cholesteryl esters and triglycerides from HDL
lipoprotein particles to LDL particles; LDLR, encoding
the LDL receptor, which is responsible for cellular uptake
of LDL particles from the bloodstream; LPL, encoding
lipoprotein lipase, which hydrolyzes triglycerides in
chylomicrons and VLDL particles, converting the latter to
LDL particles, as well facilitating cellular lipoprotein
uptake; MTP, encoding microsomal triglyceride transfer
protein, which transfers triglycerides to nascent VLDL
particles in hepatocytes; and the apolipoprotein genes
APOA5, APOB, APOC3, and APOE, which are important
constituents of varied lipoprotein particles [25–35]. All of
these genes play credible roles in determining the size and
lipid content of LDL particles as well as other lipoprotein
particles and so might directly contribute to atherogenic
dyslipidemia.
By applying principal component analysis in the
MDC-CC, we were able to define a component represent-
ing atherogenic dyslipidemia. This enabled us to perform
genetic analyses on this specific component and thereby
identify gene variants directly linked to the dyslipidemia
profile, rather than a property of an individual lipoprotein
(such as LDL size). We took advantage of data from a
recent genome-wide association study on lipid traits, which
identified 30 genetic loci strongly linked to one or more of
the blood LDL-C, HDL-C, and triglyceride levels [36]. We
assessed the strength of association between SNPs in each
of these genetic loci and the atherogenic dyslipidemia
component. We found that variants in six loci, harboring
the CETP, LPL, APOA5, LIPC, GALNT2, and MLXIPL
genes, were highly associated with this component. In
confirmation, each of the SNPs at these genes was also
associated with small/medium LDL particle concentrations
and—in the opposite direction—large HDL particle con-
centrations as well as HDL-C and/or triglycerides [23].
Interestingly, the variants at all but two of the six genes
(CETP and APOA5) were not associated with LDL-C.
Thus, the MDC-CC study validated several of the genes
previously linked to LDL size as also having variants
associated with atherogenic dyslipidemia, as well as iden-
tifying a few novel candidate genes. The implicated genes
may interact in biological pathways that regulate the dif-
ferent components of the dyslipidemia profile; conceivably,
interventions targeting one or more of these specific genes
may modulate an individual’s lipid/lipoprotein profile in a
clinically favorable way and reduce the risk of CVD, even
if they do not affect blood LDL-C levels.
Effects of Diet on Atherogenic Dyslipidemia
An important question is whether alterations in diet—
whether in regard to carbohydrate, fat, or saturated fat
content—have predictable effects on lipoprotein profiles
and, specifically, atherogenic dyslipidemia. This has
implications for nutritional counseling for patients at risk
for CVD: which diets are likely to induce or worsen ath-
erogenic dyslipidemia and thereby increase CVD risk, and
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thus should be avoided, and which diets may reverse the
dyslipidemia and should be recommended. A related
question is whether particular diets are of greater or less
benefit in individuals with atherogenic dyslipidemia com-
pared to those without it.
In one study, 105 healthy middle-age men were placed
on high-fat (46% of calories from fat), low-carbohydrate
and low-fat (24% of calories from fat), high-carbohydrate
diets in a crossover design in which they experienced
6 weeks on each diet [37]. To simplify the interpretation of
the study results, the proportions of types of fat (unsatu-
rated vs. saturated, 1:1 ratio) and types of carbohydrates
(simple vs. complex, 1:1) remained fixed in these diets.
Across all subjects, there were significantly higher levels of
triglycerides and the LDL3/LDL4 subfractions (small and
very small LDL particle concentrations), as well as lower
HDL-C levels, while on the low-fat diet compared to the
high-fat diet. Thirty-six subjects who were pattern A or
intermediate (as judged by LDL peak particle diameter)
when on the high-fat diet converted to pattern B on the
low-fat diet; all of the individuals who were pattern B on
the high-fat diet remained pattern B on the low-fat diet. In a
follow-up study, the individuals who had been pattern A on
both the high-fat and low-fat diets were subjected to a very-
low-fat diet (10% of calories from fat, with replacement by
carbohydrates) [38]. One-third of the subjects converted to
pattern B on this diet. Thus, reduction of fat along with
increased carbohydrate intake altered lipoprotein profiles
towards atherogenic dyslipidemia.
Of interest, individuals who were pattern B on a high-fat
diet, when compared to those who were pattern A on a
high-fat diet, experienced a much larger reduction in
LDL-C when on a low-fat diet [37]. This was confirmed in
both men and in pre-menopausal women, with a two- to
threefold greater reduction in LDL-C observed [39, 40].
This phenomenon appeared to be the consequence of
differential effects on lipoprotein profiles. Pattern A indi-
viduals experienced a larger decrease in LDL1 (large LDL
particle concentrations) and an increase in LDL3 (small
LDL particle concentrations) with little change in LDL2
(medium-large particle concentrations), whereas pattern B
individuals displayed a decrease in LDL2 with a smaller
decrease in LDL1 and no change in LDL3. Besides
explaining the discrepancy in LDL-C alteration, these
observations also explain why many pattern A individuals
converted to pattern B (35%) but not vice versa (6%).
Extrapolating across all of these studies, the prevalence
of pattern B increases with the amount of dietary carbo-
hydrate and decreases with the amount of dietary fat.
However, in these studies the changes in the proportions of
calories derived from fat were largely balanced by reci-
procal changes in calories from carbohydrates, making it
difficult to determine whether dietary fat or carbohydrates
are the major influence on atherogenic dyslipidemia. A
study in 178 overweight men shed some light on this
question. When compared on a higher-carbohydrate diet
(54% of calories from carbohydrates, 1:1 simple:complex)
versus a lower-carbohydrate diet (39% of calories from
carbohydrates, 1:1 simple:complex), between which the
difference was made up of protein calories (15 vs. 29%)
rather than fat (minimal change), the subjects had a higher
prevalence of pattern B when on the higher-carbohydrate
diet [41]. This observation suggests that dietary carbohy-
drates are the principal driver of atherogenic dyslipidemia.
A more complete analysis with the 178 overweight men
was highly informative as to the effects of varying carbo-
hydrates and saturated fat, as well as weight loss, on
lipoprotein profiles [42]. Four diets were compared: (1)
54% of calories from carbohydrates (1:1 simple:complex)
with low saturated fat, (2) 39% of calories from carbohy-
drates (1:1 simple:complex) with low saturated fat, (3) 26%
of calories from carbohydrates (1:1 simple:complex) with
low saturated fat, and (4) 26% of calories from carbohy-
drates (1:1 simple:complex) with high saturated fat. Diets
(1) and (2) had equal fat content, diets (3) and (4) had equal
fat content that was higher than that of diets (1) and (2).
The subjects underwent a weight-maintenance phase of
3 weeks on the assigned diets, followed by a weight-loss
phase of 5 weeks (with a subsequent four-week weight
stabilization period) on the same diets.
During the weight-maintenance phase, the subjects on
the low-carbohydrate diets [(3) and (4)] experienced sig-
nificant decreases in their triglyceride levels as well as their
LDL3 and LDL4 levels (small and very small LDL particle
concentrations); the individuals on the higher-carbohydrate
diets displayed only modest changes. In contrast, during the
weight-loss phase, the individuals on higher-carbohydrate
diets experienced larger decreases in triglycerides and
small LDL particle concentrations than did those on low-
carbohydrate diets. Thus, by the end of the study, the
higher-carbohydrate subjects had ‘‘caught up’’ with the
low-carbohydrate subjects. The lower the dietary carbo-
hydrate content, the lower the prevalence of pattern B, both
after the weight-maintenance phase and after the weight-
loss phase, although the differences in the prevalence of
pattern B were smaller after weight loss, again pointing to a
‘‘catch-up’’ phenomenon.
Comparing the low-saturated-fat and high-saturated-fat
low-carbohydrate diets [(3) vs. (4)], there were essentially
no differences in changes in triglycerides, small LDL
particle concentrations, or prevalence of pattern B, either in
the weight-maintenance or weight-loss phases [42]. This
finding indicates that dietary saturated fat content has little
influence on the components of the atherogenic lipoprotein
phenotype. This agrees with the results of a study that
compared the effects of four-week treatments with a
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high-saturated-fat diet (38% of calories from fat, with 20%
of calories from saturated fat), a monounsaturated fatty
acid (MUFA) olive oil-rich diet (38% of calories from fat,
with 22% of calories from MUFA), and a high-carbohy-
drate diet (30% of calories from fat, with\10% of calories
from saturated fat, and 55% of calories from carbohy-
drates) in 84 individuals [43]. (In all diets, *40% of the
carbohydrate calories came from simple carbohydrates, the
remainder from complex carbohydrates.) There were no
differences in triglycerides, LDL size, or prevalence of
pattern B between the high-saturated-fat and high-MUFA
diets; in contrast, both high-fat diets yielded higher LDL
sizes than the high-carbohydrate diet, with one-third of the
subjects converting from pattern A to pattern B with the
high-carbohydrate diet. The lack of difference in LDL size
seen between the two high-fat diets is consistent with
two earlier studies, one of which noted a minimal increase
in LDL size with a high-MUFA diet compared to a
high-saturated-fat diet [44], the other of which reported no
difference [45].
Finally, analysis of a prospective cohort study (the
Framingham Heart Study) confirmed that fat content in the
diet, after multivariable adjustment for carbohydrate intake
and a variety of other potential confounders, did not sig-
nificantly affect LDL size or triglyceride levels in either
men or women [46]. This was true regardless of the quality
of fat studied—total fat, saturated fat, MUFA, or polyun-
saturated fatty acid (PUFA) content. Thus, it appears that
both the quantity and quality of fat consumed (assuming no
change in the number of calories obtained from carbohy-
drates) have minimal effects on the atherogenic lipoprotein
phenotype.
Although it is possible that different types of carbohy-
drates may have different effects on lipoproteins, none of
the discussed studies were able to shed light on this
question, since in all cases the ratio of simple to complex
carbohydrates was kept constant among the experimental
diets. Given that carbohydrate intake appears to be the
primary driver of atherogenic dyslipidemia, it would be
desirable for future studies to directly compare diets in
which the proportions of different types of carbohydrates
are varied, with the overall number of calories coming
from carbohydrates being held constant.
In conclusion, either lowering the dietary carbohydrate
content or losing weight appears to attenuate atherogenic
dyslipidemia (although there does not appear to be an
additive effect of the two), whereas altering the total fat or
saturated fat content has little influence. However, being
placed on a lower-fat, higher-carbohydrate diet appears to
result in lower LDL-C levels than a higher-fat, lower-car-
bohydrate diet, particularly for individuals starting with
pattern B. Thus, it remains unclear whether having high or
low dietary carbohydrate content is more beneficial for
cardiovascular health. It should be noted that the
intervention studies described above were all short-term
(weeks) and so were not able to compare long-term CVD
outcomes resulting from the various diets. Thus, we await
long-term studies before these data can be used to help
shape nutritional recommendations for patients at CVD
risk.
Interactions of Genetics and Dietary Interventions
Given that both genetics and diet contribute to the
atherogenic lipoprotein phenotype, it is natural to expect
that there may be interactions between the two factors. For
example, individuals with specific variants in a gene may
experience changes in lipoprotein concentrations when
placed on a particular diet, whereas individuals with other
variants in the gene may be resistant to the effects of that
diet. Another possibility is that individuals with one set of
genetic variants may experience different types of lipo-
protein changes than individuals with a different set of
genetic variants, when all are placed on the same diet. This
might manifest, for instance, as some individuals being
more prone than others to developing atherogenic dyslipi-
demia on a high-carbohydrate diet. Although data is sparse
in regard to whether such interactions exist, some limited
work suggests that interactions may play an important role
in determining lipoprotein profiles and may thus be infor-
mative for CVD risk prediction. For example, knowledge
of a patient’s genetic information may allow medical
providers and nutritional counselors to predict what lipo-
protein changes are likely to occur if the patient starts a
particular dietary intervention and, thus, better advise the
patient regarding lifestyle changes.
In one study, 50 individuals with pattern A lipoprotein
profiles, offspring of 29 sets of parents, were tested for
induction of pattern B with a very-high-carbohydrate diet
[47]. Notably, all six of the subjects who converted to
pattern B were descended from two pattern B parents.
Quantitatively, LDL peak particle size decreased to a
greater degree in offspring of two pattern B parents than in
offspring of two pattern A parents. These findings suggest
that there is a heritable basis for the induction of athero-
genic dyslipidemia by a carbohydrate-rich diet.
A more detailed study was performed to examine the
interaction of varied dietary fat content and variation in the
APOA5 gene, one of the genes previously linked to ath-
erogenic dyslipidemia [39, 48]. An uncommon DNA
sequence variant in APOA5 (*6% frequency in individu-
als of European descent) that alters the 19th amino acid of
the apoA-V protein from serine to tryptophan, termed
APOA5*3, was compared to the usual variant at the DNA
base, termed APOA5*1. Individuals who had a genotype of
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*1/*3 (one of each variant), when compared to individuals
with *1/*1 (two copies of the usual variant) had higher
small LDL particle concentrations and triglycerides, as
well as higher prevalence of pattern B, regardless of
whether they were on a low-fat or high-fat diet. Also, there
were higher small LDL particle concentrations and tri-
glycerides and higher prevalence of pattern B when com-
paring all individuals on a low-fat diet compared to those
on a high-fat diet. However, there were no differences in
the relative changes of small LDL particle concentrations
and triglycerides—or relative rates of pattern B—between
*1/*3 and *1/*1 individuals on low-fat versus high-fat
diets.
Thus, while both the *3 allele and, separately, a low-fat
diet influenced the lipoprotein profile towards atherogenic
dyslipidemia, there was no evidence for an interaction
between genotype and diet. Interestingly, the only signifi-
cant difference seen in the relative changes of lipoproteins
between the two genotype groups on fat-varied diets was
with the LDL2 subfraction (corresponding to medium-large
LDL particle concentrations), where *1/*3 subjects expe-
rienced a threefold greater decrease in LDL2 than *1/*1
subjects when on a low-fat diet versus a high-fat diet [39].
Thus, APOA5 did not appear to affect dietary induction of
atherogenic dyslipidemia, though it did modulate dietary
effects on some lipoproteins.
A somewhat different analysis in the Framingham Heart
Study examined both the APOA5*3 variant as well as a
different variant that alters a DNA base in the APOA5
promoter (–1131T [ C, termed APOA5*2) with respect to
potential interactions with dietary fat intake in modulating
lipoproteins [46]. Individuals with the APOA5*2 variant
displayed increased triglycerides and smaller LDL size
when the dietary PUFA content was [6% (by calories);
individuals without the variant showed no differences with
varied PUFA intake. There were no interactions of the
APOA5*2 variant with total fat, saturated fat, or MUFA
intake, nor were there any interactions of the APOA5*3
variant with any type of fat.
Thus, while both of the APOA5 studies discussed here
suggest that APOA5 does influence the dietary effects of fat
intake on lipoproteins, they disagree on the effects of
specific gene variants. This highlights a critical problem in
the study of gene-diet interactions, the lack of consistency
between studies. In this example, the two studies differed
in study design (one was a short-term interventional study,
the other an observational prospective cohort study), the
types of diets examined (one focused only on total fat
intake, the other on total fat as well as specific types of fat),
the variants examined (one focused only on APOA5*3, the
other on both APOA5*2 and APOA5*3), the measurement
of lipoproteins (one assessed each of the LDL subfractions,
the other only LDL size), and the populations studied (one
focused on overweight men, the other on a population-
based sample).
As such, it is difficult to draw any firm conclusions
from any one gene-diet study in the absence of replication
by another study that examined the same question using
similar methodologies. For example, one study demon-
strated that a Mediterranean-style, MUFA-rich diet com-
pared to a high-carbohydrate diet increased LDL size
in individuals with certain APOE gene variants but
decreased LDL size in those with other APOE variants;
[43] this is potentially a clinically important observation,
but no confirmatory study has yet emerged, calling this
observation into doubt. As pointed out by others, the field
would greatly benefit from increased collaboration and
coordination of studies among international nutrition
researchers [49].
Conclusion
Atherogenic dyslipidemia appears to be an important inde-
pendent risk factor for CVD, confirmed by principal com-
ponent analysis of lipoprotein subfractions in a large
prospective cohort study. As the genetic basis of lipoprotein
metabolism becomes better understood, gene variants con-
tributing to atherogenic dyslipidemia are being identified;
these genes may serve as therapeutic targets to modulate the
adverse effects of the dyslipidemia. It is clear that either
reduction of dietary carbohydrate content or weight loss will
improve an atherogenic dyslipidemic profile, whereas spe-
cifically altering fat or saturated fat content may have little
influence. We await long-term clinical trials to assess whe-
ther genetic and/or dietary interventions with the intent of
modifying the dyslipidemia will ultimately translate into
reduction of CVD risk.
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